Metagenomi, Inc. (MGX)

6.22 -0.82 (-11.63%) As of 03:00PM EDT. Market open.

Metagenomi, Inc.

5959 Horton Street
7th Floor
Emeryville, CA 94608
United States
510-871-4880
https://www.metagenomi.co

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 236

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Brian Charles Thomas Ph.D.	Co-Founder, CEO & Chairman of the Board	859.34k	N/A	1969
Dr. Jian Irish M.B.A., Ph.D.	President, COO & Director	729.82k	N/A	1964
Dr. Sarah B. Noonberg M.D., Ph.D.	Chief Medical Officer	591.49k	N/A	1968
Dr. Jak Knowles M.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Ms. Pamela M. Wapnick M.B.A.	Chief Financial Officer	N/A	N/A	1966
Dr. Luis G. Borges Ph.D.	Chief Scientific Officer	N/A	N/A	1962
Mr. Simon Harnest M.Sc.	Chief Investment Officer & Senior VP of Investor Relations	N/A	N/A	1987
Mr. Matthew L. Wein J.D.	Vice President of Corporate Legal, Compliance & Corporate Secretary	N/A	N/A	1971
Dr. Alan Brooks Ph.D.	Senior Vice President of Preclinical	N/A	N/A	1966
Dr. Christopher Brown	Head of Discovery	N/A	N/A	1989

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Corporate governance

Metagenomi, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.